@article{37e78ecb17214acdafecda46ee35b029,
title = "Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis",
keywords = "B-CELL LYMPHOMA, NON-HODGKIN-LYMPHOMA, DOUBLE-HIT LYMPHOMA, LEPTOMENINGEAL DISEASE, AGGRESSIVE LYMPHOMA, ELDERLY-PATIENTS, YOUNG-PATIENTS, PHASE-II, RITUXIMAB, METHOTREXATE, 3122 Cancers",
author = "Sirpa Lepp{\"a} and Judit Jorgensen and Anne Tierens and Leo Meriranta and Ingunn {\O}stlie and Brown, {Peter de Nully} and Unn-Merete Fagerli and Larsen, {Thomas Stauffer} and Susanna Mannisto and Lars Munksgaard and Martin Maisenholder and Kaija Vasala and Peter Meyer and Mats Jerkeman and Magnus Bjorkholm and Oystein Fluge and Sirkku Jyrkklo and Knut Liestol and Elisabeth Ralfkiaer and Signe Spetalen and Klaus Beiske and Marja-Liisa Karjalainen-Lindsberg and Harald Holte",
year = "2020",
month = may,
day = "12",
doi = "10.1182/bloodadvances.2020001518",
language = "English",
volume = "4",
pages = "1906--1915",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "9",
}